+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dengue Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • PDF Icon

    Report

  • 150 Pages
  • October 2023
  • Region: Global
  • Lucintel
  • ID: 5909863

Dengue Vaccine Trends and Forecast

The future of the global dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 12.1% from 2024 to 2030. The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Dengue Vaccine by Segment

The study includes a forecast for the global dengue vaccine by type, treatment, distribution channel, end use, and region.

Dengue Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Live Attenuated Vaccine
  • Chimeric Live Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine
  • Nucleic Acid Based Vaccine

Dengue Vaccine Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Diuretic
  • Anti-Allergic
  • Blood Thinners
  • Others

Dengue Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Dengue Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Dengue Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Dengue Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dengue vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dengue vaccine companies profiled in this report include-
  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Dengue Vaccine Market Insights

The publisher forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.
Within this market, hospital will remain the largest segment due to increasing healthcare services including immunizations and growing focus towards preventative care and need for higher-quality healthcare services.
APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Features of the Global Dengue Vaccine Market

  • Market Size Estimates: Dengue vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Dengue vaccine market size by various segments, such as by type, treatment, distribution channel, end use, and region in terms of ($B).
  • Regional Analysis: Dengue vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, treatments, distribution channels, end uses, and regions for the dengue vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dengue vaccine market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q.1 What is the dengue vaccine market size?
Answer: The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for dengue vaccine market?
Answer: The global dengue vaccine market is expected to grow with a CAGR of 12.1% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the dengue vaccine market?
Answer: The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

Q4. What are the major segments for dengue vaccine market?
Answer: The future of the dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key dengue vaccine market companies?

Answer: Some of the key dengue vaccine companies are as follows:

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche
Q6. Which dengue vaccine market segment will be the largest in future?
Answer: The publisher forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Q7. In dengue vaccine market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the dengue vaccine market by type (live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid based vaccine), treatment (diuretic, anti-allergic, blood thinners, and others), distribution channel (hospital pharmacy, online pharmacy, and retail pharmacy), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Global Dengue Vaccine Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Dengue Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Dengue Vaccine Market by Type
3.3.1: Live Attenuated Vaccine
3.3.2: Chimeric Live Attenuated Vaccine
3.3.3: Inactivated Vaccine
3.3.4: Subunit Vaccine
3.3.5: Nucleic Acid Based Vaccine
3.4: Global Dengue Vaccine Market by Treatment
3.4.1: Diuretic
3.4.2: Anti-Allergic
3.4.3: Blood Thinners
3.4.4: Others
3.5: Global Dengue Vaccine Market by Distribution Channel
3.5.1: Hospital Pharmacy
3.5.2: Online Pharmacy
3.5.3: Retail Pharmacy
3.6: Global Dengue Vaccine Market by End Use
3.6.1: Hospitals
3.6.2: Homecare
3.6.3: Specialty Clinics
3.6.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Dengue Vaccine Market by Region
4.2: North American Dengue Vaccine Market
4.2.1: North American Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
4.2.2: North American Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.3: European Dengue Vaccine Market
4.3.1: European Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
4.3.2: European Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.4: APAC Dengue Vaccine Market
4.4.1: APAC Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
4.4.2: APAC Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
4.5: ROW Dengue Vaccine Market
4.5.1: ROW Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
4.5.2: ROW Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Dengue Vaccine Market by Type
6.1.2: Growth Opportunities for the Global Dengue Vaccine Market by Treatment
6.1.3: Growth Opportunities for the Global Dengue Vaccine Market by Distribution Channel
6.1.4: Growth Opportunities for the Global Dengue Vaccine Market by End Use
6.1.5: Growth Opportunities for the Global Dengue Vaccine Market by Region
6.2: Emerging Trends in the Global Dengue Vaccine Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Dengue Vaccine Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dengue Vaccine Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Mylan
7.2: BIO-MED
7.3: Teva Pharmaceutical
7.4: Sanofi
7.5: Novartis
7.6: GSK
7.7: F. Hoffmann-La Roche

Companies Mentioned

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...